4 september 2020
Our commitment in the special situation – diagnostics, medicines, vaccines
read more
Leading in research & development
Facts & Figures

13 years

It takes an average of 13 years before a medicine with a new active substance comes to market.

A strong economic framework
Facts & Figures

5,4%

is the direct contribution of the pharmaceutical sector to the gross domestic product (GDP), making it one of Switzerland's most significant private-industry sectors.

A strong economic framework
Messages

The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.

Healthcare system
Messages

People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.

show more articles

Our topics

Putting the focus on patients

Our mission is to ensure that all patients in Switzerland receive the best possible medicines and therapies for their needs as quickly as possible as part of their basic health insurance cover. For this to happen, medicinal products need to be authorised promptly by Swissmedic, basic health insurance needs to cover products from day 1 of authorisation, and there need to be sustainable models to reward innovations.We ensure that these medicinal products and therapies are of the highest possible quality. And we play our part in making sure that the cost of these therapies remains commensurate with the benefit they offer for patients, society and the economy.

Leader in research and development

Pharmacological and technological innovations will lead to rapid improvements in medicinal products. Digitalisation, in particular, will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research. These will create great potential for medical progress and benefits for patients. A concerted effort by all players is needed in order to implement this potential.

A strong economic framework

Switzerland and the pharmaceutical industry have been travelling a successful path together for decades. An economic policy that provides attractive framework conditions has favoured the impressive development of the research-based pharmaceutical industry. At the same time, the pharmaceutical industry is a pillar of the economy, contributing to Switzerland’s prosperity to an above-average degree.The pharmaceutical industry will continue to need optimum framework conditions in the future, and Switzerland needs successful companies. Political stability, legal certainty, open export markets, the availability of a qualified workforce and an attractive fiscal landscape are all factors that play a major role in this symbiosis.

Healthcare system

Nowadays, we are living longer and better in Switzerland because the population is benefiting from innovative medicinal products and has access to high-quality healthcare. Yet there is a need for action and improvement in a number of areas, and there are new challenges that are in urgent need of solutions. These include, for example, promotion of a world-leading ecosystem for health data, flexible reimbursement models for innovations and more intensive cooperation with the authorities.

Recent publications

Health monitor 2019

Download

Swiss Healthcare

Download

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2019

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more

Contact

Contact us

read more

Media

Latest information and media contacts for media representatives

read more